CRDF · Cardiff Oncology, Inc. · Executive Compensation
$1.21
+0.00 (+0.00%)
At close · Sep 11
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has performed an analysis and concluded that there exists a substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Market Cap
$94.13M
Shares
77.80M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Mark Erlander | CEO | $3,023,344 |
| Roger Sidhu | CMO | $2,273,805 |
| James Levine | CFO | $1,545,615 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Mark Erlander | CEO | $2,401,376 |
| Fairooz Kabbinavar | CMO | $1,272,897 |
| James Levine | CFO | $1,266,364 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Mark Erlander | CEO | $1,547,772 |
| Fairooz Kabbinavar | CMO | $1,257,453 |
| James Levine | CFO | $917,719 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Tod Smeal | CSO | $2,086,833 |
| Mark Erlander | CEO | $1,590,347 |
| James Levine | CFO | $959,479 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Mark Erlander | CEO | $3,635,198 |
| James Levine | CFO | $2,467,695 |
| Vicki Kelemen | COO | $1,829,877 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Mark Erlander | CEO | $1,150,703 |
| Vicki Kelemen | COO | $749,619 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Thomas H. Adams | CEO | $1,304,634 |
| Mark Erlander | CSO | $852,951 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Mark Erlander | CSO | $908,524 |
| Thomas H. Adams | CEO | $377,192 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Mani Mohindru, Ph.D. | President and Chief Executive Officer | Appointed | 2026-04-09 |
| Ajay Aggarwal, MD, MBA | Chief Operating Officer | Appointed | 2026-04-09 |
| Josh Muntner | Chief Financial Officer | Appointed | 2026-04-09 |
| Dr. Mark Erlander | director | Resigned | 2026-04-02 |
| Brigitte Lindsay | Chief Accounting Officer | Appointed | 2026-01-27 |
| Mani Mohindru | interim CEO | Appointed | 2026-01-27 |
| Roger Sidhu | Chief Medical Officer | Appointed | 2025-06-17 |
| Roger Sidhu | Chief Medical Officer | Appointed | 2025-06-17 |